Avestar Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-69,583
Closed -$6.31M 504
2024
Q1
$6.31M Buy
69,583
+16,934
+32% +$1.48M 0.66% 39
2023
Q4
$4.28M Buy
+52,649
New +$4.13M 0.49% 43

Other funds holding PPH

Avestar Capital's PPH Position: Q2 2024 in Review

Avestar Capital sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 69,583 shares — an estimated $6.31M sold.

Avestar Capital first reported a position in PPH in Q4 2023 and held it in 2 quarters. The position peaked at $6.31M in Q1 2024. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

  • Avestar Capital reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
  • Avestar Capital sold 69,583 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $6.31M.
  • Avestar Capital first reported a position in VanEck Pharmaceutical ETF in Q4 2023 and held it in 2 quarters.
  • Avestar Capital's VanEck Pharmaceutical ETF position peaked at $6.31M in Q1 2024.
  • 140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Avestar Capital's 13F filing for Q2 2024, filed 8 Aug 2024.